4 Triple Negative Breast Cancer Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Triple Negative Breast Cancer Studies in New York

NCT06134375Recruiting

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuva...

New York, NYPHASE1204 participantsDartmouth-Hitchcock Medical Center

View Study Details

NCT02926690Recruiting

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cance...

New York, NYPHASE170 participantsOncoTherapy Science, Inc.

View Study Details

NCT06908928Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-...

New York, NYPHASE152 participantsMabwell (Shanghai) Bioscience Co., Ltd.

View Study Details

NCT06637306Recruiting

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety...

New York, NYEARLY_PHASE115 participantsRima Patel

View Study Details

About Triple Negative Breast Cancer Clinical Trials in New York

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.

There are currently 4 triple negative breast cancer clinical trials recruiting participants in New York, NY. These studies are seeking a combined 341 participants. Research is being sponsored by Dartmouth-Hitchcock Medical Center, OncoTherapy Science, Inc., Mabwell (Shanghai) Bioscience Co., Ltd. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Triple Negative Breast Cancer Clinical Trials in New York — FAQ

Are there triple negative breast cancer clinical trials in New York?

Yes, there are 4 triple negative breast cancer clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What triple negative breast cancer treatments are being tested?

The 4 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for triple negative breast cancer.

Data updated October 19, 2026 from ClinicalTrials.gov